Pirfenidone for Diabetic Nephropathy
- 1 June 2011
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 22 (6), 1144-1151
- https://doi.org/10.1681/asn.2010101049
Abstract
Pirfenidone is an oral antifibrotic agent that benefits diabetic nephropathy in animal models, but whether it is effective for human diabetic nephropathy is unknown. We conducted a randomized, double-blind, placebo-controlled study in 77 subjects with diabetic nephropathy who had elevated albuminuria and reduced estimated GFR (eGFR) (20 to 75 ml/min per 1.73 m2). The prespecified primary outcome was a change in eGFR after 1 year of therapy. We randomly assigned 26 subjects to placebo, 26 to pirfenidone at 1200 mg/d, and 25 to pirfenidone at 2400 mg/d. Among the 52 subjects who completed the study, the mean eGFR increased in the pirfenidone 1200-mg/d group (+3.3 ± 8.5 ml/min per 1.73 m2) whereas the mean eGFR decreased in the placebo group (−2.2 ± 4.8 ml/min per 1.73 m2; P = 0.026 versus pirfenidone at 1200 mg/d). The dropout rate was high (11 of 25) in the pirfenidone 2400-mg/d group, and the change in eGFR was not significantly different from placebo (−1.9 ± 6.7 ml/min per 1.73 m2). Of the 77 subjects, 4 initiated hemodialysis in the placebo group, 1 in the pirfenidone 2400-mg/d group, and none in the pirfenidone 1200-mg/d group during the study (P = 0.25). Baseline levels of plasma biomarkers of inflammation and fibrosis significantly correlated with baseline eGFR but did not predict response to therapy. In conclusion, these results suggest that pirfenidone is a promising agent for individuals with overt diabetic nephropathy.Keywords
This publication has 40 references indexed in Scilit:
- Pirfenidone Is Renoprotective in Diabetic Kidney DiseaseJournal of the American Society of Nephrology, 2009
- Serum Concentrations of Markers of TNFα and Fas-Mediated Pathways and Renal Function in Nonproteinuric Patients with Type 1 DiabetesClinical Journal of the American Society of Nephrology, 2009
- The Death Ligand TRAIL in Diabetic NephropathyJournal of the American Society of Nephrology, 2008
- Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly menActa Endocrinologica, 2008
- Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic NephropathyJournal of the American Society of Nephrology, 2007
- Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteersKidney International, 2003
- Effect of pirfenidone on the pulmonary fibrosis of Hermansky–Pudlak syndromeMolecular Genetics and Metabolism, 2002
- Captopril-induced reduction of serum levels of transforming growth Factor-β1 correlates with long-term renoprotection in insulin-dependent diabetic patientsAmerican Journal of Kidney Diseases, 1999
- Ddiabetic nephropathy as a of revrsibility of established renal lesionsCurrent Opinion in Nephrology and Hypertension, 1998
- Sequential renal biopsies in insulin-dependent diabetic patients: Structural factors associated with clinical progressionKidney International, 1995